Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 Future 3-5Y EPS without NRI Growth Rate is 127.86 as of Jul. 25, 2026. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $44.43 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 279 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 97.13% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Xvivo Perfusion AB's Future 3-5Y EPS without NRI Growth Rate is 127.86.
Xvivo Perfusion AB (OTCPK:XVIPF) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Xvivo Perfusion AB Future 3-5Y EPS without NRI Growth Rate Related Terms
XVIPF vs ABT, SYK, MDT: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 127.86 mean?
Xvivo Perfusion AB (XVIPF) has a Future 3-5Y EPS without NRI Growth Rate of 127.86 as of Jul. 25, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #8 out of 279 companies in the Medical Devices & Instruments industry, placing it in the top 2.9%.
Is Xvivo Perfusion AB's Future 3-5Y EPS without NRI Growth Rate too high?
Xvivo Perfusion AB's current Future 3-5Y EPS without NRI Growth Rate is 127.86. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.69. Xvivo Perfusion AB's value of 127.86 is 518% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #8 out of 279 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Future 3-5Y EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #8 out of 279 companies for Future 3-5Y EPS without NRI Growth Rate. This places Xvivo Perfusion AB in the top 3% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.69. Xvivo Perfusion AB's value of 127.86 is 518% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.69, based on 279 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Future 3-5Y EPS without NRI Growth Rate of 127.86 is 518% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Future 3-5Y EPS without NRI Growth Rate is 127.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $44.43, compared to a current price of $24.50 — trading 44.9% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 127.86 and 518% above the Medical Devices & Instruments industry median of 20.69. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Future 3-5Y EPS without NRI Growth Rate is 127.86 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $24.50 is trading 44.9% below its estimated GF Value™ of $44.43.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Future 3-5Y EPS without NRI Growth Rate: 127.86
GF Value™: $44.43 vs. price of $24.50 (44.9% below fair value)
Industry Position: 518% above the Medical Devices & Instruments median (#8 of 279)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
